Patents Examined by Heidi Reese
  • Crystal form of small molecule immune compound, preparation method thereof and pharmaceutical composition containing the same
    Patent number: 11192882
    Abstract: Provided in the present invention are a crystal form of a small molecule immune compound, a preparation method therefor and a pharmaceutical composition containing the same; the compound is (3Z,6Z)-3-[((E)-3-(5-tert-butyl)-1H-imidazolyl-4-yl)methylene]-6-((E)-3-(3-fluorophenyl)-2-propenylene)piperazine-2,5-dione; the crystal form thereof has stable morphology, good chemical stability, high temperature resistance, and is used for treating hyperproliferative diseases. The structural formula of the compound is as shown in formula (I).
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: December 7, 2021
    Inventors: Tian Tang, Zhiying Huang, Jing Wu, Yanping Chen, Tao Shi, Yanqing Wang, Jing'an Yang
  • Heterocyclic diazenyl pyridinone copper(II) complexes as pharmacological antitumor agents
    Patent number: 11192902
    Abstract: Heterocyclic diazenyl pyridinone copper(II)-based complexes are provided as pharmacological antitumor agents e.g. to treat breast cancer.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: December 7, 2021
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Khadijah Mohamed Khalf Al-Zaydi, Ahlam Ibrahim Difullah Al-Sulami, Maram Talal J Basha
  • Fluorescent probes for monitoring voltage by photo-induced electron transfer
    Patent number: 11187660
    Abstract: Compounds and methods for determining transmembrane potential, monitoring changes in transmembrane potential, and/or drug screening are provided. In one aspect, compounds of the invention have a structure according to the formula: E-M-A, wherein A is a fluorophore, selected from xanthenes, coumarins, cyanines, bimanes, and difuloroboradizaindacenes, charged at physiological pH; M is a molecular wire; and E is a hydrophobic moiety, wherein A and E are capable of being involved in a photo-induced, intramolecular electron transfer that quenches the fluorescence of A in response to a voltage condition. When in use, compounds of the invention are membrane-impermeant and oriented within the cell membrane such that the charged moiety localizes at the outer leaflet of the lipid bilayer and the hydrophobic moiety and molecular wire associate with the hydrophobic portion of the lipid bilayer.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: November 30, 2021
    Assignee: The Regents of the University of California
    Inventors: Evan Walker Miller, Roger Y. Tsien
  • Treatment of hearing loss by inhibition of casein kinase 1
    Patent number: 11185536
    Abstract: Methods for treating hearing loss that include administering an inhibitor, e.g., a small molecule inhibitor, of casein kinase 1, preferably in combination with a treatment that stimulates Atoh1 gene expression, e.g., a gamma-secretase inhibitor, an Atoh1 stimulatory compound, or a GSK-3-beta inhibitor.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 30, 2021
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Albert Edge, Yenfu Cheng
  • Time independent viscoelastic analysis parameter for prediction of patient outcome
    Patent number: 11187710
    Abstract: In some embodiments, the invention provides an in vitro method for identifying a patient as likely as likely to require a transfusion of at least six units of blood in six hours or less. The method comprise, consists essentially of, or consists of (a) analyzing a sample of blood from a patient with a viscoelastic analysis assay to obtain a coagulation characteristic value that is independent of time of the patient; and (b) comparing the coagulation characteristic value of the patient to a coagulation characteristic value that is independent of time of a control, wherein the coagulation characteristic value of the patient that is lower than the coagulation characteristic value of the control identifies the patient as likely to require a transfusion of at least six units of blood in six hours or less.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: November 30, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventor: Michael P. Chapman
  • Treatment of NAFLD and NASH
    Patent number: 11179359
    Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: November 23, 2021
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Brian Roberts, Xueyan Wang, Yun-Jung Choi, David Karpf, Robert Martin, Charles McWherter
  • Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
    Patent number: 11180474
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: November 23, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Tasir S. Haque, Michael A. Poss, Louis J. Lombardo, John E. Macor, Laxman Pasunoori, Sreekantha Ratna Kumar
  • Substituted triazole derivatives and uses thereof
    Patent number: 11173151
    Abstract: The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: November 16, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Marie-Pierre Collin-Kroepelin, Peter Kolkhof, Thomas Neubauer, Chantal Fuerstner, Elisabeth Pook, Matthias Beat Wittwer, Klemens Lustig, Hanna Tinel, Niels Lindner, Heiko Schirmer
  • Treatment of cancer with TOR kinase inhibitors
    Patent number: 11166950
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: November 9, 2021
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Heather Raymon, Rama K. Narla, Rajesh Chopra
  • Methods and compositions for treating ulcerative colitis
    Patent number: 11166990
    Abstract: The present disclosure provides methods and pharmaceutical compositions for treating ulcerative colitis (UC) in a subject in need thereof. In particular, the compositions described here comprise or are designed based on fecal bacteria associated with FMT-based UC treatment success or failure. Also provided are methods for screening patients for their suitability for a fecal bacteria-based UC treatment. Further provided are methods for screening fecal donors for optimized source materials for producing a fecal bacteria-based pharmaceutical composition.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: November 9, 2021
    Assignee: Finch Therapeutics Holdings LLC
    Inventor: Thomas Julius Borody
  • Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof
    Patent number: 11168072
    Abstract: A crystal form I of a morpholino quinazoline compound represented by the following formula A, a preparation method therefor and use thereof. The crystal form I has good stability and non-hygroscopicity, and the preparation method is simple and suitable for industrial production.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: November 9, 2021
    Assignee: SHANGHAI YINGLI PHARMACEUTICAL CO., LTD
    Inventors: Zusheng Xu, Yangtong Lou
  • Pyridinone derivatives and their use as selective ALK-2 inhibitors
    Patent number: 11160797
    Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: November 2, 2021
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Sylvie Chamoin, Pier Luca D'Alessandro, Mika Lindvall, Dimitrios Lizos, Nikolaus Johannes Stiefl, Sylvie Teixeira-Fouchard, Thomas Ullrich, Sven Weiler
  • 2-quinolone derived inhibitors of BCL6
    Patent number: 11161839
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: Formula I wherein X1, X2, X3, R1, R2, R3, R4 and R5 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: November 2, 2021
    Assignees: The Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology Limited
    Inventors: Benjamin Richard Bellenie, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Rosemary Huckvale, Matthew Garth Lloyd
  • Methods and compositions of bile acids
    Patent number: 11154559
    Abstract: Methods and compositions are provided for treating metabolic disorders by modulating bile acid levels. Generally, the methods and compositions can modulate bile acid levels, such as serum bile acid levels, to treat a metabolic disorder. In one embodiment, a method of modulating a bile acid level includes measuring a bile acid level and delivering a composition effective to modulate the bile acid level. A method for modulating a bile acid profile includes comparing a bile acid profile to a target profile and delivering a bile acid cocktail to increase bile acid levels. In another embodiment, a pharmaceutical composition for increasing bile acid levels includes a bile acid cocktail effective to increase bile acid levels. The composition is further useful as part of an implantable system.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: October 26, 2021
    Assignees: Ethicon Endo-Surgery, Inc., The General Hospital Corporation
    Inventors: Lee M. Kaplan, Nadia N. Ahmad, Jason L. Harris, Kevin D. Felder, Alessandro Pastorelli
  • Bile salt hydrolase probe and method of making and using the same
    Patent number: 11155573
    Abstract: Probe embodiments for targeting, identifying, and isolating enzymes exhibiting BSH activity as well as devices and kits that use the probes are described herein. Methods of making and using the probes, devices, and kits are also described. In some embodiments, probes, devices, and kits for targeting, identifying, and isolating enzymes in a biological sample are disclosed. In some embodiments, compositions and methods of treatment using the probes, devices, and kits disclosed herein are described.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 26, 2021
    Assignee: Battelle Memorial Institute
    Inventors: Aaron T. Wright, Kristoffer R. Brandvold, Susan Ramos-Hunter
  • Ribociclib salts and solid state forms thereof
    Patent number: 11155545
    Abstract: The present disclosure relates to Ribociclib solid state forms, Ribociclib salts including Ribociclib succinate and solid state forms thereof, as well as processes for preparation thereof and pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: October 26, 2021
    Assignee: Sicor—Societa Italiana Corticosteroid s.r.l.
    Inventors: Helena Ceric, Elisa Vergani, Paolo S. Tiseni, Hana Kantor, Piero Paravidino, Nikolina Janton, Christian Galluzzo, Alexandr Jegorov
  • Therapeutic compounds and methods of use thereof
    Patent number: 11149002
    Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: October 19, 2021
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe Andrez, Philippe Bergeron, Paul Robert Bichler, Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Wei Gong, Michael Edward Grimwood, Abid Hasan, Ivan William Hemeon, Qi Jia, Brian Salvatore Safina, Shaoyi Sun, Michael Scott Wilson, Alla Yurevna Zenova
  • Substituted triazole derivatives and uses thereof
    Patent number: 11149023
    Abstract: The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: October 19, 2021
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Marie-Pierre Collin-Kroepelin, Peter Kolkhof, Thomas Neubauer, Chantal Fuerstner, Elisabeth Pook, Matthias Beat Wittwer, Heiko Schirmer, Hanna Tinel
  • Antagonists of the muscarinic acetylcholine receptor M4
    Patent number: 11149022
    Abstract: Disclosed herein are substituted 7-azaspiro[3.5]nonane compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: October 19, 2021
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Aaron M. Bender, Julie L. Engers
  • Solid state forms of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride and their processes for the preparation thereof
    Patent number: 11149026
    Abstract: The present invention relates to solid state forms of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride compound of formula-1a and their processes for the preparation thereof and an improved process for the preparation of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride. The present inventors also provides an amorphous polymorph of the combination drug consisting of 2?-deoxy-5-(trifluoromethyl) uridine and 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione monohydrochloride and its process for the preparation.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: October 19, 2021
    Assignee: MSN LABORATORIES PRIVATE LIMITED, R&D CENTER
    Inventors: Thirumalai Rajan Srinivasan, Eswaraiah Sajja, Venkat Reddy Ghojala, Rajeshwar Reddy Sagyam, Srinivasulu Rangineni, Rajashekar Kommera, Markandeya Bekkam